Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.7M | $86.5M | $114.9M | $106.7M | $125.6M | $117.3M | $145.1M | $127.3M |
| Cost of revenue | $26.1M | $30.2M | $31.9M | $36.3M | $44.0M | $52.4M | $68.3M | $65.5M |
| Gross profit | $36.5M | $56.2M | $83.0M | $70.4M | $81.5M | $64.9M | $76.8M | $61.8M |
| Gross margin | 58.3% | 65.0% | 72.3% | 66.0% | 64.9% | 55.3% | 52.9% | 48.6% |
| R&D | $24.6M | $34.7M | $46.9M | $61.6M | $68.0M | $62.9M | $69.5M | $70.8M |
| Operating income | −$41.2M | −$41.2M | −$38.2M | −$69.4M | −$82.7M | −$88.0M | −$108.2M | −$152.2M |
| EBITDA | −$39.0M | −$38.3M | −$34.8M | −$65.7M | −$30.1M | −$93.6M | −$107.0M | −$143.6M |
| Net income | −$45.6M | −$47.1M | −$43.6M | −$77.4M | −$40.7M | −$110.1M | −$115.3M | −$159.5M |
| Net margin | -72.7% | -54.4% | -37.9% | -72.5% | -32.4% | -93.8% | -79.4% | -125.4% |
| EPS (diluted) | -2.40 | -2.34 | -1.84 | -2.78 | -1.18 | -2.82 | -2.54 | -3.44 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $273M | $-0.64 | $-0.64–$-0.64 | 2 |
| 2027 | $348M | $-0.61 | $-0.61–$-0.61 | 2 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds NSTG.
No tracked institution reports a position in NSTG as of their last filing.
No one on the platform has traded NSTG yet.
| $5M |
| — |
| NEUPNeuphoria Therapeutics Inc. | $4.40 | -3.72% | $24M | — |
| NVTAInvitae Corporation | $0.02 | -35.59% | $5M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.